Report Viewer

NINDS CDE Notice of Copyright
Migraine Physical Function Impact Diary (MPFID)
Availability
Please contact desaip@amgen.com for more information on how to access this instrument.
Classification
Exploratory: Headache
Short Description of Instrument
The Migraine Physical Function Impact Diary (MPFID) is a 13-item self-administered instrument that assesses the impact of migraine on everyday activities and physical impairment in the past 24 hours.
 
The MPFID was developed in accordance with recommendations in the United States (US) FDA guidance for PRO instruments to support labeling claims (FDA, 2009) and best practices recommended to ensure content validity (Patrick et al, 2011a; Patrick et al, 2011b). It was developed with patient input and refined through an iterative process using both qualitative and quantitative methods. Development and validation of the MPFID also included guidance from PRO development experts and experts involved in clinical management of adults with migraine.
Scoring
MPFID items are rated on a 5-point scale based on duration or level of difficulty of migraine impact on everyday acts and tasks. Two domain scores, the impact on EA (based on 7 items) and Physical Impairment (PI; based on 5 items), as well as an overall impact of migraine on global assessment of everyday activities (G-EA) score based on a single item can be generated.  Item responses for each domain are summed and transformed to a 0 – 100 scale, where higher scores indicate greater negative impact of migraine. The daily scores are averaged over 28 days to generate a mean monthly MPFID score for each domain.
Psychometric Properties
MPFID scores exhibited high internal consistency (a>0.90) and good test-retest reliability among stable subjects (ICCs=0.70). Convergent validity was demonstrated by moderate correlations (r=±0.50; p<0.0001) between MPFID scores and number of migraine days, headache days, bed days, and other migraine-related PRO instruments. MPFID scores differentiated between groups who varied by number of migraine days, migraine interference levels, migraine pain intensity, and median split groups of scores based on other PROs instruments (p<0.05).
References
FDA. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regis. 2009;74:65132-65133.
 
Kawata AK, Hsieh R, Hareendran A, Bender R, Shaffer S, Sapra S, Desai P, Widnell K, Bayliss M, Buse D, Revicki, D. Psychometric Properties of the Migraine Physical Function Impact Diary (MPFID). Qual Life Res. 2016;25:28.
 
Kawata AK, Hsieh R, Bender R, Shaffer S, Revicki DA, Bayliss M, Buse DC, Desai P, Sapra S, Ortmeier B, Hareendran A. Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary. Headache. 2017;57(9):1385-1398.
 
Hareendran A, Mannix S, Skalicky A, Bayliss M, Blumenfeld A, Buse DC, Desai PR, Ortmeier BG, Sapra S. Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID). Health Qual Life Outcomes. 2017;15(1):224.
 
Mannix S, Oko-Osi H, Gleeson S, Skalicky A, Desai P, Sapra S, Bayliss M, Buse D, Hareendran A. The Migraine Physical Function Impact Diary: content validity of a new instrument to evaluate the benefit of preventive migraine treatments. Cephalalgia. London, UK: Sage Publications Ltd, 2016:32-33.
 
Mannix S, Skalicky A, Buse DC, Desai P, Sapra S, Ortmeier B, Widnell K, Hareendran A: Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches. Health Qual Life Outcomes. 2016;14:143.
 
Oko-Osi H, Arnold B, Savic L, Desai P, Hareendran A, Mannix S, Sapra S, Eremenco S. Translation and linguistic validation of the Migraine Physical Function Impact Diary (MPFID) for use in 25 countries. Qual Life Res. 2016;25:28-29.
 
Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring, L. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. Value Health. 2011a;14:967-977.
 
Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity-- establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. Value Health. 2011b;14:978-988.

 

Document last updated April 2020